tbuckley/cabot-search huggingface dataset:
Single fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS boost for large brain metastases: A multi-institutional analysis.
Authors: Roshan Sudhir Prabhu, Robert H. Press, Kirtesh R. Patel, Scott P Lankford, Robert Jeffery McCammon, Ben James Moeller, John Henry Heinzerling, Carolina E Fasola, Anthony L. Asher, Scott D Wait, Ashley Love Sumrall, Walter John Curran, Hui-Kuo George Shu, Ian R. Crocker, Stuart Burri
Journal: Journal of Clinical Oncology (2016)

2076 Background: SRS dose is typically limited by brain metastasis (BM) size. Any benefit for the addition of surgery to SRS for large BM in patients (pts) with oligometastatic brain disease is not well characterized. Methods: Large BM was defined as ≥ 4 cc (2 cm diameter) prior to the study. The records of consecutive pts treated with single fraction SRS alone or surgery with either pre-operative (pre-SRS) or post-operative SRS (post-SRS [collectively SRS boost]) between 2005 - 2013 from 2 institutions were reviewed. Pre-SRS dose was 20% reduced compared to standard SRS dosing, with planned resection within 48 hours. Overall survival (OS) analysis used the Kaplan-Meier method. Otherwise, cumulative incidence with competing risk was used. Results: Overall, 250 pts with 260 treated large BM were included, of which 66 were treated with SRS alone and 194 with surgery and SRS boost (65 pre-SRS, 129 post-SRS). Median imaging follow-up period was 29 months for alive pts. Groups were well balanced except for lesion volume (GTV, median 5.9 cc vs. 9.3 cc, p < 0.001), median number of BM (1.5 vs. 1, p = 0.006), and median SRS dose (18 vs. 15 Gy, p < 0.001), respectively. Local recurrence (LR) was significantly lower with SRS boost (1-year LR: 36.7% vs. 18.8%, p = 0.004), which remained significant in multivariate analysis (MVA, hazard ratio [HR]: 0.33, 95% confidence interval (CI): 0.17–0.62, p < 0.001). There was no difference in radiation necrosis (RN) by resection status, but post-SRS had significantly increased RN rate compared with pre-SRS or SRS alone (reference) in MVA (HR: 2.9, 95% CI: 1.04-8.5, p = 0.05, 1-year RN: 22%, 4.8%, 12.3%, p < 0.001, respectively). OS was significantly higher with SRS boost (2-year OS: 35.5% vs. 19.5%, p = 0.013), which remained significant in MVA (HR 0.57, 95% CI 0.36-0.89, p < 0.01). Conclusions: Surgical resection with SRS boost (either pre-SRS or post-SRS) is associated with significantly reduced LR and improved OS compared with SRS alone for large ( ≥ 4 cc) BM, despite larger average lesion size in the SRS boost group. Post-SRS was associated with the highest rate of RN. Surgical resection with SRS boost may improve outcomes in pts with a limited number of large BM.
Polydopamine Coated Single-Walled Carbon Nanotubes as a Versatile Platform with Radionuclide Labeling for Multimodal Tumor Imaging and Therapy
Authors: He Zhao, Yu Chao, Jingjing Liu, Jie Huang, Jian Pan, Wanliang Guo, Jizhi Wu, Mao Sheng, Kai Yang, Jian Wang, Zhuang Liu
Journal: Theranostics (2016)

Single-walled carbon nanotubes (SWNTs) with various unique properties have attracted great attention in cancer theranostics. Herein, SWNTs are coated with a shell of polydopamine (PDA), which is further modified by polyethylene glycol (PEG). The PDA shell in the obtained SWNT@PDA-PEG could chelate Mn(2+), which together with metallic nanoparticulate impurities anchored on SWNTs offer enhanced both T1 and T2 contrasts under magnetic resonance (MR) imaging. Meanwhile, also utilizing the PDA shell, radionuclide (131)I could be easily labeled onto SWNT@PDA-PEG, enabling nuclear imaging and radioisotope cancer therapy. As revealed by MR & gamma imaging, efficient tumor accumulation of SWNT@PDA-(131)I-PEG is observed after systemic administration into mice. By further utilizing the strong near-infarared (NIR) absorbance of SWNTs, NIR-triggered photothermal therapy in combination with (131)I-based radioisotope therapy is realized in our animal experiments, in which a remarkable synergistic antitumor therapeutic effect is observed compared to monotherapies. Our work not only presents a new type of theranostic nanoplatform based on SWNTs, but also suggests the promise of PDA coating as a general approach to modify nano-agents and endow them with highly integrated functionalities.
Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions.
Authors: Amod Sarnaik, Georgina Crago, Hao Liu, Krithika Nandakumar Kodumudi, Amy Weber, Timothy McCardle, Jeffrey S. Weber, Shari Pilon-Thomas
Journal: Journal of Clinical Oncology (2014)

9028 Background: Intralesional (IL) therapy is under investigation to treat dermal and subcutaneous metastatic cancer. In our murine model, IL injection of PV-10 (10% Rose Bengal) induced regression of injected and uninjected "bystander" melanomas. We observed a consistent increase in anti-tumor T cell responses following IL PV-10 in the mouse model, supporting an immune-based mechanism by which PV-10 mediates regression of uninjected "bystander" tumors. Methods: We translated these findings into a pilot clinical trial that enrolled 8 patients with dermal and/or subcutaneous metastatic melanoma. Two study lesions in each patient were sampled by biopsy pre-treatment; one of the two lesions was injected with IL PV-10, then both residual sites were completely excised. We compared tumors before and after treatment with H&E staining to determine pathologic complete response (pCR), and we confirmed results with MelanA immunohistochemistry. Peripheral blood mononuclear cells (PBMC) before and after IL PV-10 were phenotyped for activation markers by flow cytometry. Results: Treatment with IL PV-10 led to pCR in the post-treatment biopsies of both PV10-injected and uninjected study lesions in 4 of the 8 patients, and all 8 exhibited at least partial regression of the injected lesion. IL PV-10 was associated with an increase in circulating cytotoxic CD3+/CD8+ T cells (paired t test, p=0.008). Pre and post PV-10 treated PBMC from one patient were re-stimulated with autologous tumor in vitro. Compared to pre-treatment, PV-10 treatment produced an increase in tumor-specific interferon-gamma release by ELISA. Six of 8 patients had metastatic disease refractory to previous ipilimumab, anti-PD-1 and/or vemurafenib therapy. Four of these 6 patients exhibited pCR to PV10 in both the injected and uninjected lesions. Conclusions: IL PV-10 treatment can lead to systemic anti-melanoma immunity and pCR in injected and uninjected lesions including treatment-refractory tumors. Further studies are ongoing to determine the mechanism by which PV-10 increases tumor-specific T cell responses as well as to establish the interaction of intralesional PV-10 with combination checkpoint protein inhibition. Clinical trial information: NCT01760499.
Post-traumatic Stress Disorder, Bronchodilator Response, and Incident Asthma in World Trade Center Rescue and Recovery Workers
Authors: Rafael E. de la Hoz, Yunho Jeon, Gregory E. Miller, Juan P. Wisnivesky, Juan C. Celedón
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Post-traumatic stress disorder (PTSD) has been associated with asthma in cross-sectional studies. Whether PTSD leads to clinically significant bronchodilator response (BDR) or new-onset asthma is unknown.We sought to determine the relationship between probable PTSD and both BDR and incident asthma in a high-risk cohort of World Trade Center workers in New York (NY).This study was conducted on data from a high-risk cohort of 11,481 World Trade Center workers in New York, including 6,133 never smokers without a previous diagnosis of asthma. Of the 6,133 never smokers without asthma, 3,757 (61.3%) completed a follow-up visit several years later (mean = 4.95 yr, interquartile range = 3.74-5.90 yr). At the baseline visit, probable PTSD was defined as a score 44 points or greater in the PTSD Checklist questionnaire, and BDR was defined as both a change of 12% or greater and an increment of 200 ml or greater in FEV1 after bronchodilator administration. Incident asthma was defined as a self-report of new physician-diagnosed asthma after the baseline visit. Multivariable logistic regression was used for the analysis of probable PTSD and baseline BDR or incident asthma. Measurements and Main and Results: At baseline, probable PTSD was associated with BDR among all participants (adjusted odds ratio = 1.43; 95% confidence interval = 1.19-1.72), with similar results among never smokers without asthma. Among 3,757 never smokers, probable PTSD at baseline was associated with incident asthma, even after adjustment for baseline BDR (odds ratio = 2.41; 95% confidence interval = 1.85-3.13). This association remained significant in a confirmatory analysis after excluding 195 subjects with baseline BDR.In a cohort of adult workers exposed to a severe traumatic event, probable PTSD is significantly associated with BDR at baseline and predicts incident asthma.
Relative bone loss during aromatase inhibitors therapy: The B-ABLE cohort.
Authors: Sonia Servitja, Elisabet Torres, Dani Prieto-Alhambra, Maria Rodriguez-Sanz, Maria Martinez-Garcia, Iria Gonzalez Maeso, Adolf Diez-Perez, Xavi Nogues, Ignacio Tusquets
Journal: Journal of Clinical Oncology (2014)

579 Background: Estrogen deprivation induced by aromatase inhibitors (AI) leads to a rapid and prolonged bone loss and increased fracture incidence. The current study aims to evaluate AI-associated bone loss throughout the first two years of the treatment. Methods: B-ABLE is a prospective cohort of caucasian, postmenopausal women with early breast cancer, in adjuvant treatment with AI (according to the ASCO guidelines). Bone mineral density (BMD) and x-ray were measured at baseline and every year up to and 1 year after treatment completion. Paired t-tests were carried out to detect differences in lumbar spine (LS) and femoral neck (FN) BMD loss of 1 and 2 years of follow-up relative to baseline. Bisphosphonate users were excluded for these analyses. Women over 65 years old were also excluded from the analyses of LS BMD to avoid the underestimation of bone loss due to osteoarthritis. Results: Patients had mean rates of LS BMD loss relative to baseline of 1.98% (n=241) at 1 year and 3.51% (n=182) at 2 years of follow-up, (P<0.001). Mean rates BMD loss for FN were 1.24% (n=381) at 1 year and 2.07% (n=257) at 2 years, (P<0.001). Previous tamoxifen treated patients (40.7%) were younger and had a higher baseline BMD but experienced higher LS BMD loss rates at 1 (83%, P<0.05) and 2 (92%, P<0.001) years. FN BMD loss rates were also higher for those patients previously treated with tamoxifen at 1 (349%, P<0.001) and 2 years (177%, P<0.01). Conclusions: Rapid bone loss occurs in the first 2 years of AI treatment, especially in tamoxifen pre-treated women.
Retrospective analysis of elderly patients (pts) with primary epithelial ovarian cancer (EOC) age 70 or older.
Authors: A. Katz, H. Yu, K. Elsahwi, E. Ratner, D. Silasi, A. Santin, M. Azodi, T. Rutherford, P. E. Schwartz, M. M. Abu-Khalaf
Journal: Journal of Clinical Oncology (2010)

e15518 Background: EOC frequently affects older women with maximum incidence in the eighth decade of life. Elderly pts have been reported to receive suboptimal therapy due to concerns for toxicity. The purpose of the study is to evaluate how elderly EOC pts at Yale-New Haven Hospital (YNHH) tolerated standard chemotherapy with paclitaxel (P) and carboplatin (C). Methods: Pts age ≥ 70 years, diagnosed with EOC in years 1996-2009 were identified through the Tumor Board Registry of YNHH. Charts were reviewed to determine if any patients required a dose reduction or discontinuation of treatment. Demographic data and clinical data including stage, histology, grade, dose, cycles, need for dose reduction, toxicities, co-morbidities, progression-free (PFS) and overall survival(OS) were obtained. These factors were analyzed using the statistical software of SAS version 9.1 to determine if age plays a factor in the treatment and outcome of women receiving standard PC chemotherapy. Results: 78 of 100 pts identified received chemotherapy at YNHH, with 82% pts received C AUC = 5, 13% C AUC ≥ 6, 84% P 175 mg/m2, and 6% P 135 mg/m2. We found 87% pts completed 6 cycles of therapy, 21% pts required a dose reduction and 31% of dose reductions were due to hematologic toxicities. Pts were analyzed in age groups of 70-74, 75-79, and ≥ 80, with 42%, 27% and 31% of pts in each group respectively. There was no statistical difference between these groups in requiring dose reductions (18%, 24%, and 21%, p = 0.8819), however there was a significant difference in % of pts completing a total of 6 cycles (82%, 86%, and 96% respectively, p = 0.02). Univariate analyses were performed looking at dose reduction and cycle completion versus stage (p = 0.2 and p= 0 .5), histology (p = 0.9 and p = 0.3), and number of comorbidities (p = 0.2 and p = 0.7). Conclusions: The majority of pts age ≥ 70 completed planned 6 cycle of standard PC therapy and tolerated it well. Age should not be a limiting factor in recommending standard dose and number of cycles of chemotherapy for elderly EOC pts. No significant financial relationships to disclose.
Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up
Authors: N Biran, S Jacobus, D H Vesole, N S Callander, R Fonseca, M E Williams, R Abonour, M S Katz, S V Rajkumar, P R Greipp, D S Siegel
Journal: Blood Cancer Journal (2016)

Abstract In Eastern Cooperative Oncology Group-ACRIN E4A03, on completion of four cycles of therapy, newly diagnosed multiple myeloma patients had the option of proceeding to autologous peripheral blood stem cell transplant (ASCT) or continuing on their assigned therapy lenalidomide plus low-dose dexamethasone (Ld) or lenalidomide plus high-dose dexamethasone (LD). This landmark analysis compared the outcome of 431 patients surviving their first four cycles of therapy pursuing early ASCT to those continuing on their assigned therapy. Survival distributions were estimated using the Kaplan–Meier method and compared with log-rank test. Ninety patients (21%) opted for early ASCT. The 1-, 2-, 3-, 4- and 5-year survival probability estimates were higher for early ASCT versus no early ASCT at 99, 93, 91, 85 and 80% versus 94, 84, 75, 65 and 57%, respectively. The median overall survival (OS) in the early versus no early ASCT group was not reached (NR) versus 5.78 years. In patients &lt;65 years of age, median OS in the early versus no early ASCT groups was NR in both, hazard ratio 0.79, 95% confidence interval: (0.50, 0.25). In patients ⩾65 years of age, median OS in the early versus no early ASCT was NR versus 5.11 years. ASCT dropped out of statistical significance ( P= 0.080). Patients opting for ASCT after induction Ld/LD had a higher survival probability and improvement in OS regardless of dexamethasone dose density.
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial
Authors: Guillaume Cayla, Thomas Cuisset, Johanne Silvain, Florence Leclercq, Stephane Manzo-Silberman, Christophe Saint-Etienne, Nicolas Delarche, Anne Bellemain-Appaix, Grégoire Range, Rami El Mahmoud, Didier Carrié, Loic Belle, Geraud Souteyrand, Pierre Aubry, Pierre Sabouret, Xavier Halna du Fretay, Farzin Beygui, Jean-Louis Bonnet, Benoit Lattuca, Christophe Pouillot, Olivier Varenne, Ziad Boueri, Eric Van Belle, Patrick Henry, Pascal Motreff, Simon Elhadad, Joe-Elie Salem, Jérémie Abtan, Hélène Rousseau, Jean-Philippe Collet, Eric Vicaut, Gilles Montalescot
Journal: The Lancet (2016)
A Clinical Appraisal of the Vectorcardiogram in Myocardial Infarction
Authors: PAUL G. HUGENHOLTZ, CLAUDE E. FORKNER, HAROLD D. LEVINE
Journal: Circulation (1961)

Two-hundred six patients with myocardial infarction were studied with the Frank vectorcardiographic lead system and the standard 12-lead electrocardiogram in common use. Distinctive and statistically significant measurements separated these individuals from normal controls, similarly studied. Of 125 patients with convincing evidence of past myocardial infarction all showed abnormal vectorcardiograms. Only 76 of these presented electrocardiograms, diagnostic of infarction at the time of the diagnostic vectorcardiogram. Eleven (9.6 per cent) showed no evidence of infarction in their electrocardiographic tracings. The theory is held by some that modern vectorcardiography should be superior to conventional electrocardiography. The present observations in suspected myocardial infarction suggest that this method may yield confirmatory evidence in most cases, additional and complementary data in some, and decisive information not otherwise available, in a few.
Noninvasive Approach to Assess Coronary Artery Stenoses and Ischemia
Authors: Marc Dewey, Oliver Gaemperli, Peter Schlattmann
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Assessing the Benefit of Vascular Closure Devices After Femoral Artery Puncture
Authors: Eric K. Hoffer
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma
Authors: Meletios A. Dimopoulos, Antonio Palumbo, Katja Weisel, Enrique M. Ocio, Michele Cavo, Paolo Corradini, Michel Delforge, Albert Oriol, Hartmut Goldschmidt, María Jesús Blanchard, Chantal Doyen, Gareth J Morgan, Mathew Simcock, Neil Miller, Ana Slaughter, Teresa Peluso, Lars Sternas, Mohamed H. Zaki, Philippe Moreau
Journal: Blood (2014)
PI(4,5)P2 Is Translocated by ABCA1 to the Cell Surface Where It Mediates Apolipoprotein A1 Binding and Nascent HDL Assembly
Authors: Kailash Gulshan, Gregory Brubaker, Heather Conger, Shuhui Wang, Renliang Zhang, Stanley L. Hazen, Jonathan D. Smith
Journal: Circulation Research (2016)

The molecular mechanism by which ATP-binding cassette transporter A1 (ABCA1) mediates cellular binding of apolipoprotein A-I (apoA1) and nascent high-density lipoprotein (HDL) assembly is not well understood.To determine the cell surface lipid that mediates apoA1 binding to ABCA1-expressing cells and the role it plays in nascent HDL assembly.Using multiple biochemical and biophysical methods, we found that apoA1 binds specifically to phosphatidylinositol (4,5) bis-phosphate (PIP2). Flow cytometry and PIP2 reporter-binding assays demonstrated that ABCA1 led to PIP2 redistribution from the inner to the outer leaflet of the plasma membrane. Enzymatic cleavage of cell surface PIP2 or decreased cellular PIP2 by knockdown of phosphatidylinositol-5-phosphate 4-kinase impaired apoA1 binding and cholesterol efflux to apoA1. PIP2 also increased the spontaneous solubilization of phospholipid liposomes by apoA1. Using site-directed mutagenesis, we found that ABCA1's PIP2 and phosphatidylserine translocase activities are independent from each other. Furthermore, we discovered that PIP2 is effluxed from cells to apoA1, where it is associated with HDL in plasma, and that PIP2 on HDL is taken up by target cells in a scavenger receptor-BI-dependent manner. Mouse plasma PIP2 levels are apoA1 gene dosage-dependent and are >1 μM in apoA1 transgenic mice.ABCA1 has PIP2 floppase activity, which increases cell surface PIP2 levels that mediate apoA1 binding and lipid efflux during nascent HDL assembly. We found that PIP2 itself is effluxed to apoA1 and it circulates on plasma HDL, where it can be taken up via the HDL receptor scavenger receptor-BI.
The cooperative breeding perspective helps in pinning down when uniquely human evolutionary processes are necessary
Authors: Judith Maria Burkart, Carel P. van Schaik
Journal: Behavioral and Brain Sciences (2016)

Abstract The cultural group selection (CGS) approach provides a compelling explanation for recent changes in human societies, but has trouble explaining why our ancestors, rather than any other great ape, evolved into a hyper-cooperative niche. The cooperative breeding hypothesis can plug this gap and thus complement CGS, because recent comparative evidence suggests that it promoted proactive prosociality, social transmission, and communication in Pleistocene hominins.